This morning, Revive Therapeutics (CSE: RVV) released an update in relation to its ongoing study of Bucillamine for the use as a treatment against infectious diseases. The company intends to conduct human clinical trials in regions where the company has regulatory approval to investigate in clinical studies, which includes both the United States as well as the Asia Pacific Countries (APAC).
Revive is currently working towards advancing the clinical development of Bucillamine for the use as a treatment against infectious disease. The drug currently has a known safety profile after being used for over 30 years as a treatment against arthritis. Previously, Revive has studied the effectiveness of Bucillamine as a treatment for acute gout flares, which was done via a Phase 2 study in the US under an investigative new drug (IND) application with the FDA.
The company has currently applied for a provisional patent within the US for the use of Bucillamine as a treatment against infectious disease, titled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62/991,996), for which the lead indication has been marked as being COVID-19. Early analysis of the chemical makeup of Bucillamine has pointed to the drug potentially having greater potential to preventing acute lung injury during influenza infection than current antiviral interventions.
Most recently, the company selected Pharm-Olam as the contract research organization (CRO) that will further the clinical study of Bucillamine. The company, which has conducted over 100 clinical studies with over 19,000 patients, will study the use of Bucillamine for the treatment of infectious disease. This followed the announcement of Revive adding Dr David Boulware as a scientific adviser. Boulware is notably the principal investigator on a well known study of analyzing hydroxychloroquine for its post-exposure effects on the coronavirus.
We have strengthened our scientific and clinical team that will allow us to pursue the clinical development of Bucillamine in the potential treatment of not only COVID-19 but also other infectious diseases and we are seeking to advance Bucillamine for COVID-19 towards a potential U.S. FDA Phase 2 clinical study and a clinical study in one of the APAC countries. Revive has built a robust product pipeline that has a particular focus on infectious diseases and rare disorders and is discovering and developing new therapeutic uses of drugs such as Bucillamine, Psilocybin and Cannabidiol. We are steadily advancing our product development programs that will unlock the potential value of Revive and we are continuing to expand our product pipeline in infectious diseases and rare disorders.
Michael Frank, CEO of Revive Therapeutics
Revive is currently finalizing its regulatory package and clinical study plan for using Bucillamine as a treatment against infectious disease. Revive intends to submit to the US FDA an IND application to study Bucillamine via a proposed Phase 2 clinical study. The company will also seek to expand the clinical investigation in Japan and South Korea, among other APAC regions.
Revive Therapeutics last traded at $0.08 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
